PDCD1 and neoplasm: The JAK inhibitor ruxolitinib was shown to significantly improve the efficacy of immune checkpoint blockade therapy by impairing systemic inflammation in the tumor microenvironment and thus upregulating CTL infiltration and activation to overcome resistance to anti-PD-1 antibodies in pancreatic cancer [226].